Protein Arginine Methyltransferase 1 (PRMT1) is the primary Type I arginine methyltransferase in mammals, responsible for over 85% of cellular asymmetric dimethylarginine (ADMA) modifications. By catalyzing the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to specific arginine residues on histones (e.g., H4R3) and non-histone substrates, PRMT1 acts as a critical transcriptional co-activator and regulator of RNA processing, DNA damage response, and signal transduction. Dysregulation of PRMT1 is strongly linked to oncogenesis, particularly in acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), and various solid tumors, making it a high-value therapeutic target.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRMT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRMT1 Active Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for high-throughput enzymatic screening and SPR binding assays. |
View PRMT1 Products |
| Gene Delivery | PRMT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to evaluate cellular methylation levels (ADMA). |
View PRMT1 Products |
| Benchmark Ab | Anti-PRMT1 Recombinant Antibody Recombinant positive control for western blot, immunoprecipitation, and intracellular target engagement validation. |
View PRMT1 Products |
| Validator | PRMT1 siRNA Set For target knockdown verification and functional rescue assay development. |
View PRMT1 Products |
| Related Target A | PRMT5 Type II PRMT. Crucial for selectivity profiling (Type I vs. Type II) and evaluating synergistic combination therapies in oncology. |
View PRMT5 Products |
| Related Target B | PRMT6 Type I PRMT homolog. Highly relevant for counter-screening to ensure the isoform selectivity of candidate Type I inhibitors. |
View PRMT6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform selectivity (avoiding off-target Type I/II PRMT inhibition) | Homolog screening panel (PRMT3, PRMT5, PRMT6) strictly verified by mass spectrometry and purity analysis. |
| Assay reproducibility in high-throughput screening (HTS) | Highly active, monomeric PRMT1 recombinant enzymes with batch-to-batch consistency and low endotoxin levels. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies and validated siRNA knockdowns included in the catalog. |
| False positives in enzymatic assays | High-purity control proteins and mutant variants available to rule out non-specific aggregators. |
Live PRMT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRMT therapeutics is intensifying, with major players shifting focus from pan-inhibitors to highly selective Type I PRMT inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant mutations and synergistic combinations. PRMT1, as the dominant Type I enzyme, remains the central node of this target class. While early clinical programs like GSK3368715 (a reversible, potent Type I PRMT inhibitor) demonstrated proof-of-concept by reducing ADMA levels, managing systemic toxicity and optimizing isoform selectivity remain critical hurdles. Future development is heavily focused on combination strategies (e.g., with immune checkpoint inhibitors or chemotherapy) and the design of next-generation covalent or allosteric inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Type I Inhibitors) | GlaxoSmithKline (GSK), Epizyme/Ipsen | DLBCL, AML, Solid Tumors | Selectivity Assay (Need Mutant vs WT Proteins and Homolog panels) |
| PROTAC / Degraders | Academic Labs, Biotech Startups | Triple-Negative Breast Cancer (TNBC) | Ubiquitination & Degradation Kinetic assays (Need high-purity PRMT1 protein) |
| Combination Therapies | Clinical Trial Sponsors | Refractory Solid Tumors | In vitro validation of pathway crosstalk (Need PRMT1/PRMT5 dual target screening) |